- Home
- ADIL vs BRTX Comparison
ADIL vs BRTX Comparison
Compare ADIL & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | BRTX |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.3M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADIL | BRTX |
|---|---|---|
| Price | $1.65 | $0.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | 94.4K | ★ 3.5M |
| Earning Date | 03-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.19 |
| 52 Week High | $3.67 | $2.04 |
Technical Indicators
Market Signals| Indicator | ADIL | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 43.49 |
| Support Level | $1.61 | $0.20 |
| Resistance Level | $2.08 | $1.18 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 3.85 | 80.48 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.